Share Name Share Symbol Market Type Share ISIN Share Description
Ideagen LSE:IDEA London Ordinary Share GB00B0CM0C50 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +3.00p +4.76% 66.00p 65.00p 67.00p 66.50p 63.75p 63.75p 233,188.00 14:09:25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 21.9 1.0 0.7 89.2 119.87

Ideagen (IDEA) Latest News (3)

More Ideagen News
Ideagen Takeover Rumours

Ideagen (IDEA) Share Charts

1 Year Ideagen Chart

1 Year Ideagen Chart

1 Month Ideagen Chart

1 Month Ideagen Chart

Intraday Ideagen Chart

Intraday Ideagen Chart

Ideagen (IDEA) Discussions and Chat

Ideagen (IDEA) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
09/12/2016 15:49:1666.2010,0006,620.00O
09/12/2016 15:04:3266.25754499.53O
09/12/2016 14:36:0865.3074.57O
09/12/2016 14:32:2965.3074.57O
09/12/2016 14:10:0765.3010,0006,530.00O
View all Ideagen trades in real-time

Ideagen (IDEA) Top Chat Posts

DateSubject
10/12/2016
08:20
Ideagen Daily Update: Ideagen is listed in the Software & Computer Services sector of the London Stock Exchange with ticker IDEA. The last closing price for Ideagen was 63p.
Ideagen has a 4 week average price of 56.70p and a 12 week average price of 55.15p.
The 1 year high share price is 66.50p while the 1 year low share price is currently 44.38p.
There are currently 181,614,428 shares in issue and the average daily traded volume is 179,809 shares. The market capitalisation of Ideagen is £119,865,522.48.
09/12/2016
07:12
multibagger: Cracking acquisition - seems to be a perfect acquisition fit :) I would expect the market to like this and add 2-3p to the share price today or the next few days ! Good luck all :)
07/12/2016
13:52
rivaldo: The share price could carry on rising up to 80p. Or it might fall back a bit. Who knows? If you're a short-term trader you might care, but otherwise....
22/8/2016
09:19
rivaldo: IDEA have been featured in Shares Magazine as follows - personally I believe 100p will come quicker than 3-4 years given the likelihood of more and bigger acquisitions, as well as organic growth: "Bright Ideagen Compliance and risk is a software niche being successfully tapped Increasing industry compliance, accountability, audit trails and risk management, organisations around the world are being pushed to embrace an ever-tightening red tape net. Little UK software specialist Ideagen (IDEA:AIM) has a wide range of off-theshelf specialised software tools smack bang in this sweet spot, and successful execution of its buy-and-build strategy should see the shares hit 70p in the next six to 12 months. The Midlands-based company concentrates on what it calls the governance, risk and compliance (GRC) space, providing information management solutions to highly regulated industries, such as healthcare, complex manufacturing, banking/finance, defence and energy. Supplying an integrated system that combines information from multiple operational sources on top of the typical internal audit and compliance functions, this leads to a detailed overview for clients of corporate risk, controls and consequence mitigation, an increasingly compelling sale once an organisation’s bosses begin to grasp the significant financial and reputational damage risk of not having adequate systems in place. PROFITABLE NICHE It’s not a particularly glamorous market in the way that, say cyber security or fintech is right now. But it is allowing the company to carve itself a successful growth path in this complex and profitable niche, with carefully-vetted acquisitions adding extra value. Ideagen secured its first major purchase back in December 2012 (£18 million Gael) but its has added other smaller bolt-ons since, including the £3.6 million (net of cash) purchase of peer Covalent. It adds compliance-heavy verticals (local government, social housing) plus a deeper footprint in the existing NHS market, bolstering recurring revenue streams to about 55% of its total going forward. And a good value bit of business it looks. An estimated 85% of Covalent’s £2.2 million most recent annual revenue is recurring, implying a purchase price of just 1.9-times those repeat sales. EYE ON VALUE It’s a typical Ideagen sort of deal and underlines the management ethos that is delivering carefully managed, rather than blistering, growth. To illustrate the point, Ideagen’s most recent full year results, to 30 April 2016, show a 52% jump in revenues to £21.9 million for the year to 30 April, 10% of which was driven from the underlying business, or organic growth in other words. This led to a 57% leap in adjusted EBITDA (earnings before interest, tax, depreciation and amortisation) to £6.3 million and improved operating cash conversion metrics, an increasingly meaningful metric in the current minvestment climate. At a pre-tax profit level the figures shot up 58% to £5.7 million, although that’s after adjusting for various perceived one-offs, such as share based payments, amortisation of acquisition intangibles and a few other bits and bobs. Investors can feel rightly chuffed about a 96% client renewals hit rate and 100 new customers won, not to mention the biggest single contract in the company’s history secured, worth £4.9 million. A previous Play of the Week in the early days of the company’s switch from the old Plus market to AIM at 16p (2 Aug 2012), that investment call went on to rack up a near 30% gain in a year to 20.625p. As the chart shows, despite a few lumps and bumps along the way, share price progress has been pretty consistent ever since, the stock earning a typical high-teens to low 20s price to earnings (PE) multiple. Extrapolate a rough 20-times PE beyond this year into the 30 April 2018 fiscal period, investors can quite reasonably expect the shares to nudge 70p over the next six to 12 months, tallying with the 69p price target of analysts at FinnCap. But being a long-run growth opportunity, it is not out of the question for Ideagen stock to touch 100p on a three to four year view. Growth: MEDIUM Serving an expanding niche and is aligning its ambitions with the large opportunity without overstepping its resources. Risk: LOW A clear focus provides opportunity as well as raising barriers to entry for competitors. Quality: HIGH High visibility from recurring revenues and decent cash generation, risk to forecasts is typically on the upside."
20/11/2015
14:20
aceofthepack: 8 million shares! The share price hasn't budged. Am I missing something?
17/9/2015
07:35
rivaldo: Dilip/GHF, it's also worth factoring in to calculations that IDEA have a fast-growing cash pile - £5.3m at 30/4/15 - to incorporate into any share price targets, not least because I'm sure IDEA are on the lookout for more earnings-enhancing acquisitions. Nice plug from Penny Share Pro's e-mailed newsletter this morning: "Ideagen lands new contracts Ideagen, a leading supplier of information management software, recently announced it’s won two new deals with a combined value of £1 million. The contracts, one with a top 4 global accounting firm and the other with a leading global petrochemicals group, are for Ideagen's Governance Risk and Compliance products. It’s another very positive step forward for the group as it continues to expand its customer base and global footprint. In our view, it shouldn’t be too long before the shares break out of their current trading range and begin a fresh leg higher."
13/9/2015
18:03
dilip40: co growing at 30%pa with high recurring income at 3.2p eps and a pe of 20 would give a share price of 64p comments?
03/9/2015
13:45
breaktwister: Share price hasn't moved on this in nearly 2 months. 2 buys at over £100k each this afternoon.
31/7/2015
09:22
rivaldo: Shares Mag are positive this week about IDEA: "Ideagen eyes record breakers Red tape software firm anticipates new business scale-up COMPLIANCE AND RISK management software supplier Ideagen (IDEA:AIM) hopes to beat its biggest contract success to date with the help of public cloud platform, Amazon Web Services (AWS). Ideagen’s software-as-a-service (SaaS) AWS-based risk and compliance toolset is called Enlighten and analysts believe it will be fundamental to the company scaling up its new business victories, and should drive the 47p share price higher. The UK Government remains committed to its ‘paperless NHS’ initiative, launched in 2013 under the previous coalition leadership, but largely driven by current conservative Secretary of State for Health, Jeremy Hunt. The aim is for a completely digitised patient records system by 2018, an objective that provides huge new business opportunities for Peak District-based Ideagen, as will expansion in other verticals, say analysts. ‘With the sales and marketing teams integrated into a single entity, management anticipates opportunities to cross-sell the group’s capabilities into existing clients and win new clients in the aviation, defence, transport and healthcare markets,’ spells out Michael Larner, an analyst at IT consultancy website TechMarketViews. Ideagen’s biggest single win to date is the £1 million deal with the Doncaster and Bassetlaw NHS Trust secured on 2 October 2014. SHARES SAYS: Rising red tape remains a big growth engine for the small cap."
22/5/2015
07:26
rivaldo: Very good news yesterday - could lead to a lot more work. I can see the share price moving back up to 45p for starters now.
21/1/2014
17:13
glasshalfull: Few interesting snippets in this article... MIDLANDS BUSINESS NEWS Ideagen bullish about growth prospects By Edward Devlin, Midlands Correspondent 20 January 2014 Business Derbyshire software supplier Ideagen's management team have told Insider they are confident about the company's outlook for its second half with revenue set to nudge closer to £10m. The acquisitive company is also on the look out for further deals with ambitions to takeover one earnings enhancing business a year, chief executive David Hornsby and finance director Graeme Spenceley added. Based in the Lime Tree Business Park in Matlock, Ideagen was admitted to AIM in July 2012. Last week (14 January 2014), the business posted a 43 per cent rise in revenue to £3.7m in its first half. It was the ninth consecutive period of growth for the group. Pre-tax profit for the six months ended 31 October 2013 was also up from £230,403 to £515,105. Adjusted EBITDA increased by 59 per cent to £1.2m. The strong organic underlying growth of 16 per cent was driven by a significant increase in revenue generated within the UK healthcare sector, Ideagen chief executive David Hornsby said at the time. Full-year forecasts for adjusted EBITDA are £2.8m, slightly weighted towards the second half, with revenue set to grow by 42 per cent to £9m, which will include contribution from the latest acquisition, software developer MSS Management Systems Services. Finance director Graeme Spenceley told Insider: "There is quite a lot in the pipeline and in procurement in terms of health service contracts already for the second half so we are confident where we think we'll be at the end of the full year." Hornsby added that Ideagen was aiming to double the share price every three years as a baseline goal, which would put shares at about 60p each in 2017 and £1.20 by 2020. He said if the company could continue to boost its earnings by about 20 per cent a year, grow organically by 10 per cent and complete one earnings enhancing acquisition then the ambition was attainable. "We are certainly looking at further acquisitions in the next six to 12 months, but it will probably be in the next financial year," Hornsby said. "We are always open to deals and if something came very quickly out of nowhere and it was very attractive then we would have a look at it; particularly if it came out of cashflow." The business has completed five transactions since 2011, including MSS in 2013 and Plumtree Group in 2012. It raised £6m at the time of the Plumtree deal from a placing to fund future acquisitions. Hornsby and Spenceley both talked up the boost the business has received since its listing to AIM in 2012. "The AIM listing has been very good," Hornsby said. "It has given us credibility and it has given us access to the capital markets. We used to be on Plus markets and we raised money on the promise from certain institutions that we would move to AIM. We raised £6m 12 months ago [at the time of the Plumtree deal], which we wouldn't have been able to do if we weren't on AIM. "I think AIM has been a very good environment for us to grow." Spenceley echoed the sentiments and the pair agreed the process wasn't for the faint hearted. However, Spenceley added that any company thinking of floating on AIM needs to use the market to their advantage. "There is no point in going to AIM and then just sitting there and doing nothing," he said. "The whole point is the access to the capital market really. You need to have a requirement for capital, otherwise it is pointless." --- Regards, GHF
Ideagen share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20161210 10:49:14